Coherus Oncology, Inc. — Investor Relations & Filings

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies. The company advances a diversified portfolio of next-generation treatments to improve outcomes for patients with cancer, particularly those with hard-to-treat tumors. Its key commercial product is LOQTORZI® (toripalimab-tpzi), a next-generation PD-1 inhibitor. LOQTORZI® is the only therapy approved by the U.S. FDA for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC), used either as a single agent or in combination with chemotherapy. Coherus's clinical pipeline includes multiple drug candidates that target the tumor microenvironment.